Using a Biologic in a Patient with Atopic Dermatitis and HSV Keratitis

Program Overview

A multidisiplinary panel is presented with a highly allergic, extremely refractory patient with atopic dermatitis (AD). Her dermatologist wants to take the next step and start her on a biologic, but she is worried about the patient’s ocular history and dupilumab’s conjunctivitis risk. Find out what the experts have to say about this doctor’s dilemma.

Credit Expired

CE Credit Expired

Expires: February 27, 2021

Target Audience

The target audience for this activity is US-based dermatologists, allergists, and immunologists, as well as NPs and PAs that diagnose and manage atopic dermatitis (AD). Primary care clinicians will also be included as a secondary audience.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management
Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, assessment of treatment response, and strategies to optimize short-term control and long-term management of the disease
Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Activity Faculty

Peter A. Lio, MD (Chair)

Assistant Professor, Clinical Dermatology and Pediatrics
Northwestern University
Feinberg School of Medicine
Ann & Robert H. Lurie Children’s Hospital
Chicago, IL

Mark Boguniewicz, MD

Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health and University of Colorado School of Medicine
Denver, CO

Eric L. Simpson, MD, MCR

Professor, Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, OR

Featured RMEI CE Activities

Climbing the Ladder to Optimal Outcomes in NTM-LD: Navigating a Clear Path from Diagnosis Thru Treatment

Halting the Vicious Vortex: Targeting Neutrophil Serine Protease Activation in Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum®

Optimizing Biologic Therapy in Children with Moderate-to-Severe Atopic Dermatitis: A Care Team Forum®

Privacy | Terms of Use